×
About 2,835 results

ALLMedicine™ Multiple System Atrophy Center

Research & Reviews  1,032 results

Longstanding Multiple System Atrophy-Parkinsonism with Limbic and FTLD-type α-Synuclein...
https://doi.org/10.1111/nan.12783
Neuropathology and Applied Neurobiology; Coughlin DG, Dryden I et. al.

Dec 1st, 2021 - Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically marked by autonomic failure and variable degrees of parkinsonism and cerebellar ataxias. The average age of onset is in the sixth decade of life with a five-year surv...

Clinical Laboratory Evaluation of Chronic Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT03648905

Nov 30th, 2021 - Objective: In dysautonomias, altered functions of one or more components of the autonomic nervous system adversely affect health. A subset of dysautonomias consists of chronic autonomic failure (CAF) syndromes. A key sign of CAF is orthostatic hyp...

Assembly of α-synuclein and neurodegeneration in the central nervous system of heterozy...
https://doi.org/10.1186/s40478-021-01291-7
Acta Neuropathologica Communications; Macdonald JA, Chen JL et. al.

Nov 26th, 2021 - Peripheral administration (oral, intranasal, intraperitoneal, intravenous) of assembled A53T α-synuclein induced synucleinopathy in heterozygous mice transgenic for human mutant A53T α-synuclein (line M83). The same was the case when cerebellar ex...

A Novel TFG Mutation in a Korean Family with α-Synucleinopathy and Amyotrophic Lateral ...
https://doi.org/10.1002/mds.28857
Movement Disorders : Official Journal of the Movement Dis... Yoo D, Lee W et. al.

Nov 16th, 2021 - Tropomyosin-receptor kinase fused gene (TFG) functions as a regulator of intracellular protein packaging and trafficking at the endoplasmic reticulum exit sites. TFG has recently been proposed as a cause of multisystem proteinopathy. Here, we desc...

see more →

Guidelines  1 results

My Treatment Approach to Multiple System Atrophy.
https://doi.org/10.1016/j.mayocp.2020.10.005
Mayo Clinic Proceedings; Coon EA, Ahlskog JE

Mar 7th, 2021 - Multiple system atrophy (MSA) is a neurodegenerative disorder primarily characterized by autonomic failure plus parkinsonism or cerebellar ataxia. The diagnosis may be challenging and is usually made at a tertiary care center. The long-term manage...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  36 results

Clinical Laboratory Evaluation of Chronic Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT03648905

Nov 30th, 2021 - Objective: In dysautonomias, altered functions of one or more components of the autonomic nervous system adversely affect health. A subset of dysautonomias consists of chronic autonomic failure (CAF) syndromes. A key sign of CAF is orthostatic hyp...

Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions
https://clinicaltrials.gov/ct2/show/NCT05110547

Nov 8th, 2021 - With the aging of the population due to an increase in longevity, the number of people with Parkinson's disease is increasing (166,712 in France, as of December 31, 2015) and the number of patients with motor or cognitive-behavioral disorders is a...

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
https://clinicaltrials.gov/ct2/show/NCT05086094

Oct 20th, 2021 - The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA). Expanded access allows patients with a serious or a life-threatening disease or condition acc...

Natural History and Disease Progression Biomarkers of Multiple System Atrophy
https://clinicaltrials.gov/ct2/show/NCT04229173

Oct 12th, 2021 - Surrogate biomarkers are objectively measured characteristics of a disease which act as indicators of the underlying pathophysiological processes responsible for disease progression. Reduced grey matter volume in putamen, cerebellum and brainstem ...

Norepinephrine Transporter Blockade, Autonomic Failure
https://clinicaltrials.gov/ct2/show/NCT02796209

Oct 12th, 2021 - Atomoxetine, a selective norepinephrine transporter (NET) blocker, increases standing blood pressure and improves neurogenic orthostatic hypotension (NOH)-related symptoms to a greater extent than midodrine, the current standard of care. Atomoxeti...

see more →

News  42 results

The First Signs of Elusive Dysautonomia May Appear on the Skin
https://www.medscape.com/viewarticle/955470

Jul 27th, 2021 - The initial manifestations of dysautonomia may be dermatologic related, so awareness of what to look for is essential. During the annual meeting of the Society for Pediatric Dermatology, Adelaide A. Hebert, MD, defined dysautonomia as an umbrella ...

Blood biomarker may predict Parkinson’s disease progression
https://www.mdedge.com/neurology/article/228309/parkinsons-disease/blood-biomarker-may-predict-parkinsons-disease
Jim Kling

Sep 10th, 2020 - A novel biomarker could help identify progression in Parkinson’s disease, distinguish it from other neurodegenerative disorders, and monitor response to treatments. Although the biomarker, neurofilament light chain (NfL), is not especially specifi.

BRIEF-Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
https://www.reuters.com/article/brief-biohavens-verdiperstat-receives-fa/brief-biohavens-verdiperstat-receives-fast-track-designation-for-the-treatment-of-multiple-system-atrophy-idUSFWN2BB0DD

Mar 18th, 2020 - March 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: * BIOHAVEN’S VERDIPERSTAT RECEIVES FAST TRACK DESIGNATION FOR THE TREATMENT OF MULTIPLE SYSTEM ATROPHY Source text for Eikon: Further company coverage:

Neurologists publish consensus statement on stridor in MSA
https://www.mdedge.com/jcomjournal/article/210121/rare-diseases/neurologists-publish-consensus-statement-stridor-msa?channel=39313
Erik Greb

Oct 15th, 2019 - An international panel of neurologists has drafted a consensus statement on the diagnosis, prognosis, and treatment of stridor in patients with multiple system atrophy (MSA). The statement was published Oct.

Neurologists publish consensus statement on stridor in MSA
https://www.mdedge.com/neurology/article/210121/rare-diseases/neurologists-publish-consensus-statement-stridor-msa
Erik Greb

Oct 15th, 2019 - An international panel of neurologists has drafted a consensus statement on the diagnosis, prognosis, and treatment of stridor in patients with multiple system atrophy (MSA). The statement was published Oct.

see more →

Patient Education  6 results see all →